The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Friedman, R. S.
Right arrow Articles by Kalos, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedman, R. S.
Right arrow Articles by Kalos, M.
The Journal of Immunology, 2004, 172: 3319-3327.
Copyright © 2004 by The American Association of Immunologists

Molecular and Immunological Evaluation of the Transcription Factor SOX-4 as a Lung Tumor Vaccine Antigen

Rachel S. Friedman1,2, Chaitanya S. Bangur1, Eden J. Zasloff, Liqun Fan, Tongtong Wang, Yoshihiro Watanabe3 and Michael Kalos4

Corixa, Seattle, WA 98104

The developmental transcription factor SOX-4 has been shown to be highly and differentially overexpressed in primary small cell lung carcinomas (SCLC). To examine the potential of SOX-4 for broad use as a lung cancer vaccine, we have evaluated the expression of SOX-4 in a panel of primary adenocarcinoma, squamous, and large cell tumor samples as well as in a panel of established small cell and non-small cell lung carcinoma tumor cell lines. SOX-4 mRNA is shown to be overexpressed in a substantial fraction of each of these lung tumor types. To examine the immunological potential of SOX-4, we have evaluated the presence of SOX-4-specific CD4 and CD8 T cells in PBMC of healthy donors and the presence of SOX4-specific Abs in sera from SCLC patients. We demonstrate the presence of both CD4 and CD8 T cells that recognize naturally processed epitopes derived from SOX-4 as well as the presence of SOX-4-specific Abs in sera from SCLC patients, but not in sera from healthy donors. The lung tumor-specific overexpression and demonstration of a comprehensive Ag-specific immune response specific for SOX-4 support the use of this molecule in the development of whole gene-, peptide-, or protein-based vaccination strategies against lung cancer. Furthermore, the identification of naturally processed T cell and Ab epitopes from SOX-4 provides valuable tools for the development of peptide-based vaccination strategies against lung cancer as well as to monitor SOX-4-specific responses in vaccinated patients.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
X. Pan, J. Zhao, W.-N. Zhang, H.-Y. Li, R. Mu, T. Zhou, H.-Y. Zhang, W.-L. Gong, M. Yu, J.-H. Man, et al.
Induction of SOX4 by DNA damage is critical for p53 stabilization and function
PNAS, March 10, 2009; 106(10): 3788 - 3793.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
D. Sinner, J. J. Kordich, J. R. Spence, R. Opoka, S. Rankin, S.-C. J. Lin, D. Jonatan, A. M. Zorn, and J. M. Wells
Sox17 and Sox4 Differentially Regulate {beta}-Catenin/T-Cell Factor Activity and Proliferation of Colon Carcinoma Cells
Mol. Cell. Biol., November 15, 2007; 27(22): 7802 - 7815.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Liu, S. Ramachandran, M. Ali Seyed, C. D. Scharer, N. Laycock, W. B. Dalton, H. Williams, S. Karanam, M. W. Datta, D. L. Jaye, et al.
Sex-determining region y box 4 is a transforming oncogene in human prostate cancer cells.
Cancer Res., April 15, 2006; 66(8): 4011 - 4019.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.